Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma

doi: 10.1097/PAI.0000000000001261

Figure Lengend Snippet: Expression analysis and expression pattern of TAGLN2 based on the Oncomine data sets. A, Expression of TAGLN2 in different human cancers in the Oncomine database. B, Expression pattern of TAGLN2 in ovarian cancer tissues based on the Oncomine database. Oncomine meta-analysis suggests that TAGLN2 is overexpressed (red) in ovarian cancer tissues compared with those in normal tissues.

Article Snippet: The TAGLN2 antibody for IHC was purchased from Novus (Cat No: NBP1-89722).

Techniques: Expressing

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma

doi: 10.1097/PAI.0000000000001261

Figure Lengend Snippet: A-D, The mRNA expression of TAGLN2 in normal tissue samples compared with ovarian cancer samples.

Article Snippet: The TAGLN2 antibody for IHC was purchased from Novus (Cat No: NBP1-89722).

Techniques: Expressing

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma

doi: 10.1097/PAI.0000000000001261

Figure Lengend Snippet: Histologic expression of TAGLN2. A, Validation of TAGLN2 expression with IHC data from The HPA database. B-D, IHC staining was done using the TAGLN2 antibody, and the percentages of samples were of different staining intensities. The staining intensity was scored as high expression (a), medium expression (b), low expression (c) and negative (d) (scale bar: 50 μm).

Article Snippet: The TAGLN2 antibody for IHC was purchased from Novus (Cat No: NBP1-89722).

Techniques: Expressing, Biomarker Discovery, Immunohistochemistry, Staining

Journal: Applied Immunohistochemistry & Molecular Morphology

Article Title: TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma

doi: 10.1097/PAI.0000000000001261

Figure Lengend Snippet: TAGLN2 knockdown decreased ovarian cancer cell proliferation, migration and cytoskeletal stability. A and B Real-time qPCR and western blot were performed to measure TAGLN2 knockdown efficiency in the Skov3 cells. C and D, Wound-healing assays were performed to evaluate the motility of the si-TAGLN2 siRNA-treated group and NC group. C, Representative images of the wound-healing assay in the 2 groups. D, Quantification of the wound-healing assay is shown. Data were presented as mean ± SD ( P < 0.01). E and F Colony formation assays showed that the colony formation of Skov3 cells was significantly decreased in the TAGLN2 siRNA-treated group compared with those in the NC group. Data were presented as mean ± SD (*** P <0.01). G, Skov3 cells transfected with negative control or si-TAGLN2 siRNAs. Phalloidin staining was performed to visualize the F-actin architecture in NC and si-TAGLN2 groups. Scale bar: 20 µm.

Article Snippet: The TAGLN2 antibody for IHC was purchased from Novus (Cat No: NBP1-89722).

Techniques: Knockdown, Migration, Western Blot, Wound Healing Assay, Transfection, Negative Control, Staining

Journal: Journal of the American Heart Association

Article Title: Multi‐Omic Insight Into the Molecular Networks in the Pathogenesis of Coronary Artery Disease

doi: 10.1161/jaha.124.037203

Figure Lengend Snippet: Figure 4. A chromosome map of TAGLN2 illustrates the effect values of SNPs within 500 kbp upstream and downstream regions, identified as eQTLs and mQTLs, in the context of coronary artery disease GWAS data. The x axis denotes the chromosomal position coordinates, whereas the y axis represents the negative logarithm of P values (including eQTLs, mQTLs, GWAS data, and SMR). The red dashed line indicates the P selection threshold of 1e-5 for eQTLs analyzed with SMR, with genes exhibiting P<1e-5 represented by red diamonds; the blue dashed line represents the P selection threshold of 0.001 for mQTLs analyzed with SMR, with methylated sites displaying P<0.001 denoted by blue solid circles. eQTL indicates expression quantitative trait loci; GWAS, genome- wide association study; mQTL, methylation quantitative trait loci; SMR, summary-data-based Mendelian randomization; and SNPs, single-nucleotide polymorphisms.

Article Snippet: Membranes were incubated with the following primary antibodies: DHX58 (1:500, Proteintech, 10 494- 1- AP), SWAP70 (1:1000, Abclonal, A14857), TAGLN2 (1:2000, Proteintech, 10 234- 2- AP), and GAPDH (1:20000, Proteintech, 10 494- 1- AP), which served as the loading control.

Techniques: Selection, Methylation, Expressing, GWAS

Journal: Journal of the American Heart Association

Article Title: Multi‐Omic Insight Into the Molecular Networks in the Pathogenesis of Coronary Artery Disease

doi: 10.1161/jaha.124.037203

Figure Lengend Snippet: Figure 6. Single-cell type expression in atherosclerotic plaque for the 5 genes identified by Mendelian randomization. A, A total of 17 cell clusters and 8 cell types based on UMAP visualization. B through C, Expression patterns of 4 genes (TAGLN2, SWAP70, DHX58, and APOB) across cell-type clusters visualized using UMAP and dot plots. D, Differential expression of 3 genes (TAGLN2, SWAP70, and DHX58) between atherosclerotic plaques and controls, shown in 8 cell types at average Log2FC >0.25 and FDR <0.05 level. FDR indicates false discovery rate; Log2FC, log2 fold change; SMC, smooth muscle cells; T/NK, T or Natural Killer cells and UMAP, uniform manifold approximation and projection.

Article Snippet: Membranes were incubated with the following primary antibodies: DHX58 (1:500, Proteintech, 10 494- 1- AP), SWAP70 (1:1000, Abclonal, A14857), TAGLN2 (1:2000, Proteintech, 10 234- 2- AP), and GAPDH (1:20000, Proteintech, 10 494- 1- AP), which served as the loading control.

Techniques: Expressing, Quantitative Proteomics

Journal: Journal of the American Heart Association

Article Title: Multi‐Omic Insight Into the Molecular Networks in the Pathogenesis of Coronary Artery Disease

doi: 10.1161/jaha.124.037203

Figure Lengend Snippet: Figure 7. Validation of gene and protein expression in the aortas of AS and control mice. A, Sequential panels show Oil Red O staining of the aorta, Oil Red O staining of the aortic valve, hematoxylin and eosin staining of the aortic valve, and Masson’s trichrome staining of the aortic valve. B, Western blot DHX58, SWAP70, and TAGLN2 protein expression in the aortic tissues of AS and control mice, with GAPDH used as a loading control. C, Quantification of DHX58, SWAP70, and TAGLN2 protein levels in the aortic tissues of AS and control mice. Data are presented as mean±SE (n=6 per group, analyzed using the Mann- Whitney U test). D, Quantification of DHX58, SWAP70, and TAGLN2 mRNA levels in the aortic tissues of AS and control mice. Data are presented as mean±SE (n=6 per group, analyzed using the Mann-Whitney U test). AS indicates atherosclerotic. KD, kiloDalton.

Article Snippet: Membranes were incubated with the following primary antibodies: DHX58 (1:500, Proteintech, 10 494- 1- AP), SWAP70 (1:1000, Abclonal, A14857), TAGLN2 (1:2000, Proteintech, 10 234- 2- AP), and GAPDH (1:20000, Proteintech, 10 494- 1- AP), which served as the loading control.

Techniques: Biomarker Discovery, Expressing, Control, Staining, Western Blot, MANN-WHITNEY

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: Expression of Transgelin-2 (TAGLN2) in the biliary tract cancer cell (BTC)-spheres. ( A ) Sphere-formation assays of BTC cell lines, including SNU245, SNU308, SNU869, and SNU1196. The cells were maintained in growth media and plated onto culture dishes or ultra-low attached plates in sphere media. ( B ) Differentially expressed genes and ( C ) proteins analyzed in sphere-cultured cells in SNU245 and SNU1196. ( D ) Tumorigenesis was performed using adherent and sphere-cultured SNU1196 in vivo. ( E ) Differentially expressed genes were analyzed using microarray analysis; 65 genes were overexpressed in both sphere cultured SNU245 and SNU1196 cells (Fold change, FC > 1.2) as well as in biliary tract cancer patient tissues (FC > 2); TAGLN2 was selected from the microarray analysis. ( F ) TAGLN2 expression in all BTC cell lines analyzed using PCR. In B, C, D, and F: Adh, adherent cells; Sph, sphere cells

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Expressing, Cell Culture, In Vivo, Microarray

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: Suppressing TAGLN2 expression reduces cell proliferation, migration, and tumorigenic ability. ( A ) The effect of TAGLN2 suppression on the expression of EMT-associated proteins, including mesenchymal markers N-cadherin, Snail, and JAG2 and epithelial marker occludin. ( B–D ) TAGLN2 suppression by shRNA reduces ( B ) cell proliferation, ( C ) migration, and ( D ) invasion; ***, P < 0.001 shTAGLN2-1- and shTAGLN2-2-transfected vs. control vector-transfected (shCon) SNU1196 cells. ( E ) Injection of shTAGLN2-1, shTAGLN2-2 cells suppressing TAGLN2 expression into mice reduces the tumor mass in treated groups compared to the shCon group; n = 5 in each group, Data represents mean ± SEM. ( F ) The expression of Ki67, a cell proliferation marker in TAGLN2 -suppressed mice tumor tissues

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Expressing, Migration, Marker, shRNA, Transfection, Control, Plasmid Preparation, Injection

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: Suppressing TAGLN2 expression reduces cancer stem cell features. ( A ) Sphere formation assay. Cells with suppressed TAGLN2 (shTAGLN2-1, -2) show a reduced number and size of spheres compared to the control vector-transfected cells. ( B ) Colony forming assay to analyze the clonogenic capacity. The colonies in shTAGLN2-1- and shTAGLN2-2-transfected SNU1196 cells were increased compared to those in control vector-transfected cells ( P < 0.001). ( C ) The expression of stemness-associated markers, including cMET, AKT, and Nanog, assessed using western blot analysis in SNU1196 and SNU308 cells with suppressed TAGLN2 expression achieved by either shRNA or siRNA. ( D) SNU245, SNU308, and SNU1196 cells treated with recombinant TAGLN2 (rTAGLN2) protein at 0, 0.04, and 4 µg/mL for 30 or 60 min. An increase in cMET, AKT, and Nanog is observed in a dose- and time-dependent manner by rTAGLN2 treatment in both cell lines

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Expressing, Tube Formation Assay, Control, Plasmid Preparation, Transfection, Western Blot, shRNA, Recombinant

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: Suppressing TAGLN2 elevates sensitivity to chemodrugs. ( A, B ) Irradiation (0, 2, 4, 6, and 8 Gy) reduces the number of colonies and the surviving fractions at different doses in cells in which TAGLN2 is suppressed using shRNA (shTAGLN2-1, -2) compared to control vector-transfected cells. ( C ) TAGLN2 expression in gemcitabine-resistant SNU1196 (SNU1196/GR). ( D ) TAGLN2 expression silenced by 150 nM siRNA in 1196/GR cells for chemosensitivity analysis. ( E) Silencing TAGLN2 expression enhances sensitivity to gemcitabine. ( F ) Combined use of TAGLN2 siRNA with chemodrugs, including 5-FU, cisplatin, oxaliplatin, and carboplatin, enhances chemosensitivity. ( G ) Combined use of TAGLN2 siRNA with chemodrugs, including irinotecan, etoposide, and erlotinib, has no effect on chemosensitivity. ( H ) Combined use of TAGLN2 siRNA with cMET inhibitor crizotinib and savolitinib enhances chemosensitivity

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Irradiation, shRNA, Control, Plasmid Preparation, Transfection, Expressing

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: TAGLN2 is overexpressed in the blood from patients with biliary tract cancer. ( A ) Dot plot for the serum level of CA19–9 in normal control and patients with biliary stone and BTC. ( B ) Dot plot for the serum TAGLN2 expression in western blot converted into an arbitrary unit by densitography using ImageJ software in normal control and patients with biliary stone and BTC. ( C ) ROC curves for TAGLN2, CA19–9, and their mathematical combination of patients with BTC versus those with benign diseases. ( D ) Distribution of TAGLN2 and CA 19 − 9 levels in patients with benign diseases (black dot) and BTC (red dot). The optimal cut-off levels of CA 19 − 9 and TAGLN2 were 37 U/mL and 1061.9 arbitrary unit, respectively. Thirty-seven CA 19 − 9 negative patients with BTC (red dots in Left upper quadrant) were diagnosed using TAGLN2 (diagnostic yield, 84.1% (37/44 cases)

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Control, Expressing, Western Blot, Software, Diagnostic Assay

Journal: BMC Cancer

Article Title: Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer

doi: 10.1186/s12885-024-12082-3

Figure Lengend Snippet: TAGLN2 expression in patient tissues and cancer-associated fibroblasts. ( A ) TAGLN2 expression in normal human tissues assessed using IHC. ( B ) Representative images show the expression of TAGLN2 in cancer cells and the stroma portion of BTC surgical tissues. ( C ) The DFS and OS by Kaplan–Meier analysis comparing low- and high-TAGLN2 IHC index in cancer and stroma, respectively. ( D ) IF findings in BTC tissue show overexpression of TAGLN2 in the stroma of BTC tissue, and its location coincided with α-SMA expression. ( E ) TAGLN2 expressed in the CAFs from BTC assessed using IF. Typical morphology of fibroblast in bright fields, expression of α-SMA and FAP, and non-expression of the epithelial marker as CK-7 in the IF study are shown

Article Snippet: TAGLN2 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA; sc-106,633) comprising a pool of a target-specific siRNA (siTAGLN2) and control siRNA-A (Santa Cruz Biotechnology; sc-37,007) at 100 pmol/L in 150 nM medium were transfected into SNU1196/GR cells using Lipofectamine RNAiMAX (Invitrogen).

Techniques: Expressing, Over Expression, Marker